Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.80 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.80 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.80 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.80 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22672737 | 1.00 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL22672736 | 1.00 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL930742 | 1.00 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL22672738 | 1.00 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL7787652 | 1.00 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL2248932 | 0.98 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911091 | 0.98 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Ammonia Solution, Strong SCHEMBL27973853 | 0.96 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911817 | 0.94 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL8314 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-4060615-A | ANTIHYPERTENSIVE, PHOSPHODIESTERASE INHIBITOR | MEAD JOHNSON & COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | CHRNB2 3256/4885CHRNA3 3246/4885CHRNA4 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.